Daiichi Sankyo Co., Ltd., Japan Vaccine Co., Ltd. and Sanofi K.K. announced that they will launch "Squarekids subcutaneous injection syringe", a 4-tetravalent combination vaccine (DPT-IPV) for the prevention of diphtheria, pertussis, tetanus and poliomyelitis (polio) on December 9, 2015.

Squarekids is a product manufactured by Kitasato Daiichi Sankyo Vaccine Co., Ltd.  This product is a combination vaccine containing DPT vaccine of Kitasato Daiichi Sankyo Vaccine and inactivated polio vaccine (Salk vaccine) of Sanofi filled in prefilled syringes, which is the first 4-tetravalent DTP-IPV combination vaccine in Japan that contains Salk inactivated polio vaccine.

Daiichi Sankyo Group, Japan Vaccine and Sanofi Pasteur, the vaccines division of Sanofi Group, are committed to contributing to protection of the health of people in Japan by bringing innovative vaccines with high medical needs and by promoting the importance of preventative medicine.

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets.

Japan Vaccine Co., Ltd. started its operations on July 2, 2012, a joint venture company equally owned by GlaxoSmithKline K.K. and Daiichi Sankyo Co., Ltd. As a company specialized in providing vaccines to prevent infectious diseases and thereby meeting social needs, Japan Vaccine is operating with a mission of "contributing to the establishment of preventive measures against communicable diseases through collaborations with diverse stakeholders."

Sanofi Group, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs.

Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe.